Skip to main content

Efficacy of rituximab in refractory antisynthetase syndrome

Buy Article:

$51.00 plus tax (Refund Policy)


We report the successful use of repeated administration of rituximab in a patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. A literature review revealed that previous experience with rituximab in this condition has been sparse. The rationale for the use of B‐cell depleting therapies in antisynthetase syndrome has been explored in light of the current understanding of the pathogenesis of this condition.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Document Type: Research Article

Affiliations: 1: Immunology Department 2: Respiratory Medicine Department, Royal Adelaide Hospital 3: Neuropathology Department, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia

Publication date: 2012-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more